EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Retinal atrophy in multiple sclerosis is similar with extended versus standard interval natalizumab therapy

Brenna McCormack iD, Omar Ezzedin, Ting-Yi Lin iD, Anna Bacchetti iD, Giulia S Moretti iD, Ernest Lievers, Ananya Gulati, Simidele Davis, Gabriel Otero-Duran, Devon J Bonair, Nicole Pellegrini, Georgios Gakis iD und 9 weitere

Multiple Sclerosis Journal – Experimental, Translational and Clinical · 2026-07 · 12 (3)

DOI: 10.1177/20552173261475496 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Multiple Sclerosis Journal – Experimental, Translational and Clinical, online erschienen am 06.08.2026. Verfasst von Brenna McCormack und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Johns Hopkins University, Baltimore, MD, USA. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Biogen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Retinal ganglion cell + inner plexiform layer (GCIPL) atrophy reflects global neurodegeneration and disability in multiple sclerosis. Extended interval dosing (EID; every 5–8 weeks) natalizumab reduces progressive multifocal leukoencephalopathy risk in people with relapsing–remitting multiple sclerosis (PwRRMS) versus standard interval dosing (SID; every 4 weeks).

Objectives

To assess if EID versus SID natalizumab differentially impacts GCIPL atrophy, other retinal layer (peripapillary retinal nerve fiber layer (pRNFL), inner nuclear layer (INL), and outer nuclear layer (ONL)) atrophy, and/or clinical outcomes in PwRRMS.

Methods

PwRRMS underwent longitudinal Cirrus high-definition optical coherence tomography (OCT), expanded disability status scale (EDSS), 100% and 2.5% contrast letter-acuity (LA) assessments. Analyses utilized mixed-effects regression models adjusting for age, sex, race, disease duration, optic neuritis history, and interval between treatment initiation and OCT monitoring, accounting for within-subject, inter-eye correlations.

Results

GCIPL and pRNFL atrophy rates were not significantly different between EID ( n = 22) and SID ( n = 109) natalizumab ( p = 0.48, p = 0.24). INL and ONL atrophy were faster with EID versus SID natalizumab ( p = 0.02, p < 0.001). Age was higher (44.8 vs. 40.1 years, p = 0.03) and disease duration longer (15.2 vs. 8.4 years, p < 0.001) in the EID natalizumab cohort. Annual EDSS and 100% and 2.5% LA changes were similar between cohorts.

Conclusion

We detected no significant difference in GCIPL or pRNFL atrophy, or clinical outcomes, between EID and SID natalizumab. Faster INL and ONL atrophy may relate to cohort demographic differences.

Schlagwörter

Stichwörter der Autor:innen

Multiple sclerosisdemyelinating diseasesnatalizumaboptical coherence tomographyrelapsing–remitting multiple sclerosistysabri

Autor:innen und Institutionen

  • Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.
  • Department of Neurological Sciences, University of Vermont, Burlington, VT, USA.

ORCID-Profile: Brenna McCormack, Ting-Yi Lin, Anna Bacchetti, Giulia S Moretti, Georgios Gakis, Angeliki Filippatou, Clare McGarvey Lambert, Martin Maurice O'Donnell, Kathryn Fitzgerald, Elias S Sotirchos, Peter A Calabresi, Scott D Newsome, Ellen M Mowry, Shiv Saidha

Förderung

  • Biogen

Zitieren

APA

McCormack, B., Ezzedin, O., Lin, T. Y., Bacchetti, A., Moretti, G. S., Lievers, E., Gulati, A., Davis, S., Otero-Duran, G., Bonair, D. J., Pellegrini, N., Gakis, G., Filippatou, A., Lambert, C. M., O'Donnell, M. M., Fitzgerald, K., Sotirchos, E. S., Calabresi, P. A., Newsome, S. D., …, & Saidha, S. (2026). Retinal atrophy in multiple sclerosis is similar with extended versus standard interval natalizumab therapy. Multiple Sclerosis Journal – Experimental, Translational and Clinical, 12(3). https://doi.org/10.1177/20552173261475496

Vancouver

McCormack B, Ezzedin O, Lin TY, Bacchetti A, Moretti GS, Lievers E, et al. Retinal atrophy in multiple sclerosis is similar with extended versus standard interval natalizumab therapy. Multiple Sclerosis Journal – Experimental, Translational and Clinical. 2026;12(3). doi:10.1177/20552173261475496

BibTeX
@article{McCormack2026,
  author = {McCormack, Brenna and Ezzedin, Omar and Lin, Ting-Yi and Bacchetti, Anna and Moretti, Giulia S and Lievers, Ernest and Gulati, Ananya and Davis, Simidele and Otero-Duran, Gabriel and Bonair, Devon J and Pellegrini, Nicole and Gakis, Georgios and Filippatou, Angeliki and Lambert, Clare McGarvey and O'Donnell, Martin Maurice and Fitzgerald, Kathryn and Sotirchos, Elias S and Calabresi, Peter A and Newsome, Scott D and Mowry, Ellen M and Saidha, Shiv},
  title = {Retinal atrophy in multiple sclerosis is similar with extended versus standard interval natalizumab therapy},
  journal = {Multiple Sclerosis Journal – Experimental, Translational and Clinical},
  year = {2026},
  volume = {12},
  number = {3},
  doi = {10.1177/20552173261475496}
}
Kostenlos starten →